Ho-Hyung Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ho-Hyung Woo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Setsuko K. Chambers
University of Arizona, College of Medicine
2 shared publications - Csaba F László
Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
1 shared publication David J. Shapiro
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724,1 Department of Biochemistry, University of Illinois, Urbana-Champaign, Illinois2
1 shared publicationIna Menzl
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724,1 Department of Biochemistry, University of Illinois, Urbana-Champaign, Illinois2
1 shared publication- Stephen Greco
Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
1 shared publication Terri Baker
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724,1 Department of Biochemistry, University of Illinois, Urbana-Champaign, Illinois2
1 shared publication
Latest Publications
- Open Access
- 1 January 2012
- Published by Springer Nature in Molecular Cancer
- Vol. 11 (1) , 58
Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152
Colony stimulating factor-1 (CSF-1) plays an important role in ovarian cancer biology and as a prognostic factor in ovarian cancer. Elevated levels of CSF-1 promote progression of ovarian cancer, by binding to CSF-1R (the tyrosine kinase receptor encoded by c-fms proto-oncogene).
- 1 January 2012
- Published by Springer Nature in Molecular Cancer
- Vol. 11 (1) , 58
Open AccessRegulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152
Colony stimulating factor-1 (CSF-1) plays an important role in ovarian cancer biology and as a prognostic factor in ovarian cancer. Elevated levels of CSF-1 promote progression of ovarian cancer, by binding to CSF-1R (the tyrosine kinase receptor encoded by c-fms proto-oncogene).
- 1 January 2011
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 31 (1) , 215-225
Posttranscriptional Suppression of Proto-Oncogene c-fms Expression by Vigilin in Breast Cancer
cis-acting elements found in 3′-untranslated regions (UTRs) are regulatory signals determining mRNA stability and translational efficiency. By binding a novel non-AU-rich 69-nucleotide (nt) c-fms 3′ UTR sequence, we previously identified HuR as a promoter of c-fms proto-oncogene mRNA. We now identify the 69-nt c-fms mRNA 3′ UTR sequence as a cellular vigilin target through which vigilin inhibits the expression of c-fms mRNA and protein. Altering association of either vigilin or HuR with c-fms mRNA in vivo reciprocally affected mRNA association with the other protein. Mechanistic studies show that vigilin decreased c-fms mRNA stability. Furthermore, vigilin inhibited c-fms translation. Vigilin suppresses while HuR encourages cellular motility and invasion of breast cancer cells. In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.
- 1 January 2011
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 31 (1) , 215-225
Posttranscriptional Suppression of Proto-Oncogene c-fms Expression by Vigilin in Breast Cancer
cis-acting elements found in 3′-untranslated regions (UTRs) are regulatory signals determining mRNA stability and translational efficiency. By binding a novel non-AU-rich 69-nucleotide (nt) c-fms 3′ UTR sequence, we previously identified HuR as a promoter of c-fms proto-oncogene mRNA. We now identify the 69-nt c-fms mRNA 3′ UTR sequence as a cellular vigilin target through which vigilin inhibits the expression of c-fms mRNA and protein. Altering association of either vigilin or HuR with c-fms mRNA in vivo reciprocally affected mRNA association with the other protein. Mechanistic studies show that vigilin decreased c-fms mRNA stability. Furthermore, vigilin inhibited c-fms translation. Vigilin suppresses while HuR encourages cellular motility and invasion of breast cancer cells. In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.